Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | CMO | November 28, 2022 | December 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date November 28, 2022 · Filed December 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,184,037 |
Reported balance
After 2022-11-30 transaction · row 1
1 source rowRow 1 · 2022-11-30 · Grant · Acquired 16,927 · Balance 2,184,037 F1: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary. |
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2032-11-28 | Direct | 2,315,439 |
Reported balance
After 2022-11-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-28 · Grant · Acquired 2,315,439 · Balance 2,315,439 F2: 241,190 shares vested on November 28, 2022; the balance will vest on a monthly basis as follows (i) 48,238 shares at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended), from November 2022 through February 2025, and (ii) 48,239 shares at the conclusion of each month of Continuous Service, from March 2025 through May 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 782,408 |
Reported balance
Holding disclosure · report date 2022-11-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 782,408 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary.
F2: 241,190 shares vested on November 28, 2022; the balance will vest on a monthly basis as follows (i) 48,238 shares at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended), from November 2022 through February 2025, and (ii) 48,239 shares at the conclusion of each month of Continuous Service, from March 2025 through May 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2018 Filed Jun 12, 2018 21:54 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0000899243-18-016228 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The options will vest in four equal quarterly installments commencing on September 1, 2018. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:07 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 97,009 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-003464 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,009 Underlying: Common Stock · 97,009 shares Expires 2028-02-07 F1 · price: On February 7, 2018, the board of directors of CytoDyn Inc. approved an amendment to its director compensation program, providing for payment in stock options, in lieu of cash, of all unpaid director retainer fees for the four-quarter period ending February 28, 2018. The number of options awarded to each director was determined by applying a price of $0.31 per option, which was the fair value estimate of the option award as of the grant date, using the Black-Scholes option pricing model. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:47 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 75,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0000899243-17-015355 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: Subject to stockholder approval, at the next annual meeting, of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, the options will vest in four equal quarterly installments commencing on September 1, 2017. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 20:31 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Option (right to buy) · Derivative | 7,123 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000899243-17-010064 · doc4.xml · derivative · entry 1 Kelly Scott A. · CIK 0001703394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,123 Underlying: Common Stock · 7,123 shares Expires 2027-04-10 F1 · derivative.exercise_date: Subject to stockholder approval of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, at the next annual meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.